Back HIV Policy & Advocacy

HIV Policy & Advocacy

China Lifts Long-standing Travel Ban on HIV Positive People

China's State Council this week lifted restrictions against HIV positive visitors dating from the late 1980s, echoing similar moves by the United States and South Korea earlier this year. The change will also apply to people with other sexually transmitted diseases and leprosy.

Read more:

California AIDS Advocates Demand that Governor Schwarzenegger Not Cut Funds for State AIDS Drug Assistance Program

In the lead-up to World AIDS Day, activists held a press conference at San Francisco City Hall demanding that Governor Arnold Schwarzenegger ensure full funding for California's AIDS Drug Assistance Program (ADAP). ADAPs receive both federal and state contributions. Historically, California has been among the most generous states, but the ongoing financial crisis could result in a "a life and death crisis" for thousands of people who rely on the program, according to Dana Van Gorder of Project Inform.

Read more:

AIDS Activists Issue Grades to Drug Companies

The majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a "report card" on the pharmaceutical industry released by the AIDS Treatment Advocates Coalition (ATAC), a non-profit AIDS advocacy group.

Read more:

President Obama Signs Ryan White Act, HIV Travel and Immigration Ban Will Be Lifted Early Next Year

On October 30, President Barack Obama signed legislation reauthorizing the Ryan White Act, which provides funding for treatment and other services for people with HIV/AIDS. During the signing ceremony, he announced that the federal government would lift the ban on HIV positive visitors or immigrants to the United States, effective in early January 2010.

Read more:

FDA Grants Tentative Approval of Generic Fixed-dose Combination of Efavirenz/emtricitabine/tenofovir

On August 12, 2009, the U.S. Food and Drug Administration (FDA) granted tentative approval for a generic fixed-dose combination pill containing 600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir -- equivalent to the brand-name Atripla coformulation.


Read more: